In this Article, Manos Perros and Ruben Tommasi are incorrectly listed as being affiliated with ‘Shire Pharmaceuticals, 300 Shire Way, Lexington, MA 02421.’ The correct affiliation is listed below:
Entasis Therapeutics, 35 Gatehouse Drive Suite E0, Waltham, MA 02415 USA
In addition, Renu Singh is incorrectly listed as being affiliated with ‘Department of Chemistry, Drug Discovery and Development Center, University of Cape Town, Rondebosch 7701, South Africa.’ The correct affiliation is listed below:
AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA
Additional information
The online version of the original article can be found at 10.1038/srep11827
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Basarab, G., Kern, G., McNulty, J. et al. Correction: Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep 5, 14157 (2015). https://doi.org/10.1038/srep14157
Published:
DOI: https://doi.org/10.1038/srep14157
